InsidersTradesSigma
IRLAB Therapeutics AB: management transactions · Finland · FIN-FSA
FI:irlab-therapeutics-abSE0025400179FI·FIN-FSAMcap 108M€Healthcare
Browse the full directors' dealings record of IRLAB Therapeutics AB, a listed issuer based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Healthcare sector, IRLAB Therapeutics AB has logged 3 insider filings. Market capitalisation: €107.7m. The latest transaction was filed on 29 July 2025 (Purchase). Among the most active insiders: Joakim Tedroff. The full history is accessible without an account.
3
Insider Decl.
0
Thresholds
€157,847
3 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
1.27 €
Analyst consensus
1 analystsStrong buy
7.50 €Target 7.50 €(+491%)7.50 €
Income statement
Revenue57.5 M€
Gross profit61.1 M€106% margin
Net income−110.0 M€-72.4% margin
Valuation
P/Book3.5x
Beta0.53
Balance sheet & cash
Market cap107.7 M€
Total debt30.0 M€
Free Cash Flow−55.2 M€
Debt / Equity68%
Profitability & ownership
ROE-300.9%
ROA-22.9%
% insiders26.2%
% institutions10.6%
Last declaration on 29 July 2025
Declarations3 total
Executives●Purchase20FIN-FSA
€11,24336,000 shares@ €0.31230.010% mcap100.0% of flow
BTA (betald tecknad aktie)
FI:A003R127-1·
Ideal exit: 21 Apr 2026 (T+270)
Executives●Purchase26FIN-FSA
€110,630357,327 shares@ €0.30960.10% mcap75.5% of flow
BTA (betald tecknad aktie)
FI:A003Q791-1·
Ideal exit: 14 Apr 2026 (T+270)
Executives●Purchase17FIN-FSA
€35,975116,196 shares@ €0.30960.033% mcap24.5% of flow
BTA (betald tecknad aktie)
FI:A003Q787-1·
Ideal exit: 13 Apr 2026 (T+270)
3 of 3 declarations